CTLA4 and cancer: Recently, wide use of immune checkpoint inhibitors (ICIs), which mainly target CTLA-4 and the programmed death receptor/ligand 1 (PD-1/PD-L1) in cancer immunotherapies, improved durable responses in some advanced cancer patients (99).